Private equity firm Arsenal Capital Partners announced that it has expanded its team with the addition of Raymond (Ray) H. Hill. Hill will work as an Operating Partner within the firm’s healthcare team and will focus on pharmaceutical services investment themes and portfolio companies.
Hill was most recently chairman and CEO of CorEvitas. Hill built CorEvitas into an industry leader that provides real-world evidence to assess the safety and clinical effectiveness of therapies in autoimmune and inflammatory-mediated diseases.
As the head of CorEvitas for nine years, he oversaw significant growth and two recapitalization events, the most recent of which was Thermo Fisher Scientific’s acquisition of CorEvitas for over $900 million.
Before CorEvitas, Hill was President of InVentiv Clinical (now Syneos Health), a leading clinical research organization. And he also served as President of IMS Health (now IQVIA) from 2003 to 2011, building IMS’ consulting and services business. Earlier in his career, he was a Partner and led A.T. Kearney’s Pharmaceutical and Healthcare practice globally. Hill graduated with a B.S. from Cornell University and holds a master’s degree in environmental management from Duke University.
KEY QUOTES:
“We are incredibly excited to welcome Ray to our team. Ray is an outstanding executive with an unparalleled track record of building market-leading, technology-enabled pharmaceutical services businesses.”
- Gene Gorbach, an Investment Partner of Arsenal
“I share Arsenal’s mission to build businesses that create long-term value for all stakeholders in the healthcare system. I look forward to supporting Arsenal across its portfolio to realize the promise of adoption of technology and data analytics across drug discovery, development, and commercialization.”
- Ray Hill
